BioCentury | Nov 3, 2014
Company News

Xcovery, Betta Pharmaceuticals deal

...Xcovery granted Betta (formerly Zhejiang Beta Pharma Co. Ltd. ) Chinese rights to Phase I/II oncology candidate X-396 . Xcovery...
BioCentury | May 20, 2013
Company News

Amgen, Zhejiang Beta Pharma Co. Ltd. sales and marketing update

...reported 2012 worldwide sales of $359 million for Vectibix. Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Zhejiang Beta Pharma Co. Ltd....
Items per page:
1 - 2 of 2
BioCentury | Nov 3, 2014
Company News

Xcovery, Betta Pharmaceuticals deal

...Xcovery granted Betta (formerly Zhejiang Beta Pharma Co. Ltd. ) Chinese rights to Phase I/II oncology candidate X-396 . Xcovery...
BioCentury | May 20, 2013
Company News

Amgen, Zhejiang Beta Pharma Co. Ltd. sales and marketing update

...reported 2012 worldwide sales of $359 million for Vectibix. Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Zhejiang Beta Pharma Co. Ltd....
Items per page:
1 - 2 of 2